Skip to content

IMRN

Immuron Ltd.

NASDAQ · Healthcare · Biotechnology · AU

$1.22
+3.39%
Ask drillr

Year over year

Reported trailing growth

Revenue
EBITDA
EBIT
EPS
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
+61.1%
EBITDA
+12.7%
EBIT
+13.3%
Net income
+28.0%
EPS
+44.4%
Free cash flow
+51.1%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026